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Abstract  Studies  of  percutaneous  cryotherapy  in  the  treatment  of  benign  or  malignant  soft
tissue tumours  are  rare  and  mainly  involve  small  populations.  Nevertheless,  results  show
cryotherapy’s  potential  in  terms  of  local  control  of  tumours,  analgesic  efﬁcacy,  reduced  intra-
and postoperative  complications,  and  reduction  in  the  length  of  convalescence  after  the  pro-
cedure. The  objective  of  this  update  is  to  set  out  the  short-term  prospects  for  this  technique  in
the treatment  of  soft  tissue  tumours,  so  that  it  may  be  more  widely  offered  in  these  indications.
© 2013  Éditions  françaises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.Imaging;
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Radiologically  controlled  percutaneous  thermal  ablation  procedures  such  as  radiofre-
quency,  microwaves  and  cryotherapy  are  increasingly  used  in  a  variety  of  indications  as
alternatives  to  surgery,  particularly  in  patients  where  surgery  is  contraindicated  or  difﬁ-
cult.
Studies  of  percutaneous  cryotherapy  in  the  treatment  of  benign  or  malignant  soft  tissue
tumours,  with  the  exception  of  organs  such  as  the  kidneys  [1],  liver  and  lungs  [2],  appear
to  date  to  be  rare,  and  mainly  involve  small  populations  [3,4]. Their  analysis,  however,
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tRadiologically  guided  percutaneous  cryotherapy  for  soft  tiss
has  meant  that  new  prospects  can  be  proposed,  particularly
for  tumours  of  soft  tissues,  bone  [5]  or  the  prostate.
Because  the  technique  is  minimally  invasive  [6],  the  fact
that  it  does  not  damage  collagenous  structures  and  the
ablation  zone  can  be  monitored  in  real  time  by  visualis-
ing  the  ice,  cryoablation  appears  to  cause  less  damage  to
surrounding  tissues  than  surgery,  particularly  as  regards  the
skin  and  nerve  structures.  In  general,  postoperative  pain  is
slight  and  recovery  after  the  procedure  is  rapid.  The  risk
of  complications  is  reduced,  partly  owing  to  easy  planning
and  monitoring  using  ultrasound  (US),  computed  tomogra-
phy  (CT)  or  magnetic  resonance  imaging  (MRI).  In  addition,
percutaneous  cryoablation  can  be  performed  under  local  or
general  anaesthesia  [7].
The  aim  of  this  update  is  less  to  provide  a  reminder
of  cryotherapy  techniques  than  to  present  the  short-term
prospects  of  this  technique  in  the  treatment  of  soft  tissue
tumours,  so  that  it  may  be  more  widely  offered  in  these
indications.
Cryotherapy of secondary locations
Soft  tissue  cryotherapy  was  initially  proposed  by  Tuncali
et  al.  [4]  for  the  management  of  bone  and/or  soft  tissue
metastases  resistant  to  the  usual  analgesic  treatment.  This
study  showed  antitumoral  and  analgesic  efﬁcacy  in  a  pop-
ulation  of  22  patients  (27  lesions  with  a  mean  long  axis  of
5.2  cm).  In  this  study,  the  treatment  was  performed  under
general  anaesthesia  with  MRI  guidance,  with  the  number  of
cryoprobes  suited  to  the  volume  of  the  lesion  (a  mean  of
1.6).  Analysis  showed  that  89%  of  the  lesions  treated  were
the  site  of  tumour  necrosis  greater  than  75%  and  that  tumour
size  regressed  in  19%  of  cases,  was  stable  in  43%  of  cases
and  increased  in  38%  of  cases.  The  mean  time  to  local  pro-
gression  was  5.5  months.  Tolerance  of  the  treatment  was
excellent  with  the  complications  observed  after  the  pro-
cedure  all  being  transient.  In  all,  two  cases  were  reported
where  the  L4  and  L5  sensory/motor  roots  were  affected  but
resolved  within  a  week,  there  were  two  cases  of  damage  to
the  perineal  nerve  which  resolved  itself  in  a  few  months,
and  one  case  of  serous  vaginal  discharge  complicated  by  a
gluteal  abscess.  In  terms  of  analgesia,  six  patients  spoke
of  complete  improvement  in  pain,  11  of  partial  improve-
ment  and  three  said  there  was  no  improvement.  The  others
were  not  symptomatic  as  regards  pre-  or  postoperative
pain.
In  another  study  by  Beland  et  al.  [8],  four  patients  were
treated  by  percutaneous  cryotherapy  under  general  anaes-
thesia  for  secondary  soft  tissue  lesions.  These  had  occurred
in  the  pelvic,  presacral,  and  axillary  areas  and  within  par-
avertebral  soft  tissue.  In  all  cases,  the  patients  reported
an  improvement  in  pain  after  cryoablation.  Local  tumour
control  could  only  be  assessed  in  two  patients  and  showed
stability  in  one  and  an  increase  in  tumour  size  after  2.5
months  in  the  other.  No  complication  was  found  apart  from
brachial  plexopathy  considered  as  admissible  at  the  time  of
treatment,  since  the  initial  lesion  was  invading  the  brachial
plexus.  In  our  experience  (with  10  patients  treated  under
general  anaesthesia),  similar  results  were  obtained,  partic-
ularly  for  painful  intercostal  locations  (Fig.  1).
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esmoid tumours
esmoid  tumours,  also  known  as  aggressive  ﬁbromatosis,
re  rare  [9].  Although  they  never  present  metastases,  the
reatment  of  extra-abdominal  desmoid  tumours  is  a  chal-
enge  due  to  locally  invasive  extension.  The  main  treatment
or  desmoid  tumours  is  surgical  ablation  with  wide  margins,
ut  local  recurrence  is  common,  even  after  apparently  com-
lete  surgical  ablation,  and  occurs  in  a mean  of  40%  of  cases
19—77%).  Cryotherapy  has  consequently  been  offered  as  an
lternative  to  surgery  (Fig.  2).
The  initial  study  by  Kujak  et  al.  [3]  reported  local  con-
rol  of  extra-abdominal  desmoid  tumours  after  cryotherapy
n  cinq  patients  who  failed  to  respond  to  standard  treat-
ents  (surgery,  radiotherapy  and  chemotherapy).  Of  the
ve  cases,  three  were  referred  for  local  tumour  control  and
wo  for  palliative  care  of  inoperable  tumours.  The  tumours
ere  located  in  the  neck,  shoulders  and  trunk  and  their
aximum  dimension  was  between  3  and  10  cm.  In  each
ase,  there  was  short  and  long-term  follow-up  of  the  size
f  the  tumour  and  evolution  of  the  pain,  the  data  being
ompared  with  the  data  before  cryotherapy.  In  all  three
atients  referred  for  local  tumour  control,  the  ablather-
py  zone  completely  and  optimally  covered  the  tumours,
nd  for  two  of  them,  their  tumours  with  long  axes  of  3
nd  4.9  cm  and  the  related  pain  had  completely  regressed
n  the  short-  (mean  of  16  months)  and  long-term  (mean
f  46  months).  The  third  patient,  whose  lesion  had  a  long
xis  of  6.1  cm,  showed  a  moderate  decrease  in  both  tumour
ize  and  pain  after  6  months.  The  two  patients  referred
or  palliative  care  obtained  partial  relief  of  pain  2  weeks
fter  the  procedure;  in  the  long-term  (58  months  follow-up),
lthough  there  was  a  signiﬁcant  reduction  in  tumour  size
f  the  ﬁrst  patient’s  initial  lesion  of  9.1  cm,  pain  returned
t  its  original  level,  which  was  described  as  moderate;  in
he  second  patient,  who  had  received  partial  treatment
f  a  10-cm  mass,  there  was  an  increase  in  tumour  size
n  the  long-term  (36-month  follow-up)  and  pain  returned
t  the  same  moderate  level  as  before  cryotherapy.  Kujak
t  al.  concluded  that  cryoablation  may  be  an  effective
lternative  to  surgery  for  the  treatment  of  extra-abdominal
esmoid  tumours  if  the  ablation  zone  completely  covers  the
umour.
In  addition  to  our  experience  with  15  procedures  under
eneral  (13  cases)  and  local  (2  cases)  anaesthesia  that
howed  similar  results  to  Kujak  et  al.’s  study,  we  recently
eported  the  possibility  of  repeated  cryotherapy  treatment
f  multiple  extra-abdominal  desmoid  tumours  in  a  sin-
le  female  patient  with  Gardner’s  syndrome  [10]. For  this
atient,  efﬁcacy  and  tolerance  were  excellent  and  there-
ore  she  had  one  of  the  procedures  under  sedation  alone.
his  observation  suggests  that  cryoablation  can  be  repeated
uccessfully  with  complete  safety  when  clinically  necessary.
n  addition,  as  indicated  by  the  absence  of  progression  of
ntreated  abdominal  lesions  present  in  this  patient,  it  seems
hat  cryoablation  does  not  promote  the  disease  outside  of
he  ablated  tumour  site.  This  point  is  particularly  impor-
ant  because  it  has  been  shown  that  surgical  trauma  was
ssociated  with  the  growth  of  untreated  tumours  and  local
ecurrence  [11]. A  multicentre  trial  should  begin  soon  to
valuate  these  data  on  a  larger  population.
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Figure 1. CT-guided cryotherapy of a secondary location for analgesia: a, b: axial CT slices showing a left thoracic paravertebral metastasis
(arrow) of colic origin with the beginnings of foraminal extension in a 56-year-old male patient with severe intercostal neuralgia; c: insertion
of two cryotherapy needles — sagittal reconstruction; d: cryotherapy needle in place with ice formation, axial CT slice without injection of
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tontrast agent. The patient described complete disappearance of p
ascular malformations
espite  the  very  preliminary  nature  of  this  type  of  proce-
ure  in  this  indication,  cryoablation  may  also  be  effective
or  relieving  symptoms,  preventing  the  growth  and/or  local
ecurrence  of  venous  vascular  malformations  (VM).  In  par-
icular  cryotherapy  could  be  an  alternative  solution  in  the
vent  of  recurrence  after  sclerotherapy  or  in  the  case  of
ascular  malformations  with  a  mainly  solid  component  [12].
In  our  experience  with  four  patients,  including  one
ecently  reported  case  [13], all  the  patients,  including  two
ecurrences,  reported  total  absence  of  pain  in  the  short-
erm  without  complications  after  cryotherapy  performed
nder  general  anaesthesia  (Fig.  3).  Patients  were  referred
fter  discussion  in  a  multidisciplinary  meeting  for  local  con-
rol  of  symptomatic  VM.  For  all  these  patients,  VM  decreased
y  more  than  90%  on  follow-up  images  obtained  6  months
fter  the  procedure.  A  single  centre  prospective  trial  is
m
t
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an the week following the procedure.
urrently  in  progress  to  validate  these  preliminary  results
n  a  larger  scale.
oft tissue sarcomas
n  the  absence  of  a  prospective  study,  the  initial  manage-
ent  of  soft  tissue  sarcomas  (STS)  is  not  at  present  a  matter
or  cryotherapy.  Nevertheless,  in  our  centre,  we  have  suc-
essfully  performed  several  procedures  in  cases  referred
o  us  of  recurrence  inoperable  under  general  anaesthesia
Fig.  4).  A  recent  feasibility  study  [14]  showed  that  in  a  popu-
ation  with  STS  relapse,  only  28%  of  patients  (13/48)  could  be
reated  in  this  way  if  the  strict  criteria  are  observed:  maxi-
um  tumour  diameter  less  or  equal  to  10  cm,  distance  of  the
umour  from  the  skin  greater  than  5  mm  and  from  neurovas-
ular  structures  greater  than  3  mm,  accessibility,  absence  of
rticular  invasion  and  volume  of  the  projected  cryoablation
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Figure 2. Ultrasound-guided cryotherapy of a desmoid tumour: a, b: T1-weighted sagittal and axial MRI images after contrast injection
showing a 35-mm recurrence (arrows) of a desmoid tumour 2 years after initial treatment in a 46-year-old man. The patient was symptomatic;
c: ultrasound-guided insertion of two cryotherapy needles. The bottom image shows the ice forming; d: T1-weighted MRI control after 6
months, with fat saturation and after contrast injection: no tumour remains can be seen. The patient was no longer in pain.
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Figure 3. Ultrasound and CT-guided cryotherapy of vascular malformation: a: T2-weighted coronal MRI with fat saturation showing a
35-mm, clearly hyperintense, intramuscular mass. This mass was symptomatic and palpable in a 45-year-old female patient. Histological
examination conﬁrmed the diagnosis of venous vascular malformation; b: T1-weighted axial slices showing the hypointense mass (arrow);
c: pretreatment axial CT scan with contrast injection showing discrete enhancement; d: axial CT slice after removing the two cryoablation
needles; e: T1-weighted axial control MRI 3 months after treatment showing a hypointense ring reﬂecting post-treatment inﬂammatory
changes; f: T1-weighted axial MRI slice after injection of contrast agent no longer showing enhancement in the treated mass. The patient
no longer reported pain 1 year after the procedure.
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Figure 4. CT-guided cryotherapy on a relapsed soft tissue sarcoma: a, b: axial MRI slices with T1 and T2 weighting after injection of
contrast agent showing a 15-mm pelvic recurrence (arrows) of a high-grade myxoid sarcoma. The patient had a history of multiple surgery (3
resections) and had already been treated with radiotherapy; c: insertion of a cryotherapy needle with ultrasound guidance; d: appearance
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did not ﬁnd any remains of the tumour.
zone  covering  the  entire  volume  of  the  lesion.  After  univari-
ate  analysis  and  comparison  with  other  patients,  locations
in  the  wall  of  the  trunk,  in  the  shoulders  and  pelvic  girdle
(P  =  0.002),  tumours  with  local  aggressiveness  (P  =  0.016),
deep  tumours  (P  =  0.002)  or  less  or  equal  to  5  cm  (P  =  0.044),
and  liposarcoma  and  myxoﬁbrosarcoma  (P  =  0.007)  subtypes
appeared  as  eligibility  criteria  for  such  a  treatment.
Conclusion
These  results  show  the  potential  of  radiologically  guided
cryotherapy  as  concerns  local  control  of  tumours,  anal-
gesic  efﬁcacy  and  reduced  intra-  and  postoperative
complications.  Because  it  is  tolerated  extremely  well,
cryotherapy  has  the  advantage  of  being  able  to  be
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c the ice covering the entire target lesion. The control at 6 months
erformed  under  local  anaesthesia  and  in  an  outpatient
linic.  In  addition,  this  minimally  invasive  technique  seems
etter  tolerated  by  nearby  structures  than  radiofrequency
r  microwave  treatment.  At  the  present  time,  the  cost  is  still
 limitation  (approximately  twice  as  expensive  as  radiofre-
uency)  but  can  be  put  into  perspective  when  compared
ith  the  costs  of  surgery  or  convalescence  for  patients  for
hom  ‘‘conventional’’  treatment  is  no  longer  an  option.  This
echnique  now  needs  to  be  validated  prospectively  and  on  a
arger  scale.isclosure of interest
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